<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493570</url>
  </required_header>
  <id_info>
    <org_study_id>1289.3</org_study_id>
    <secondary_id>2011-003749-16</secondary_id>
    <nct_id>NCT01493570</nct_id>
  </id_info>
  <brief_title>Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled Parallel-group Proof of Mechanism Study to Assess the Pharmacokinetics and to Evaluate the Pharmacodynamic Effect of Different Single Oral Doses of BI 409306 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Due to the exploratory nature of this trial, there is no primary objective in a confirmatory
      sense. The study aims

      - to evaluate the effect of different doses of BI 409306 on biomarker and to assess the
      exposure of BI 409306
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change from baseline (calculated as ratio) of biomarker</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax ratio of BI 409306 in different media</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured biomarker concentration</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to maximum measured in biomarker concentration</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured BI 409306 concentration in different media)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured BI 409306 concentration in different media)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 409306 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Film-coated tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>High dose film-coated tablet</description>
    <arm_group_label>BI 409306 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>Low dose film-coated tablet</description>
    <arm_group_label>BI 409306 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306 Placebo</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>Medium dose film-coated tablet</description>
    <arm_group_label>BI 409306 medium dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males according to the following criteria:

             Based upon a complete medical history, including the physical examination, vital signs
             after 10 minutes in supine position (BP (blood pressure), PR (pulse rate), BT (body
             temperature)), 12-lead ECG (electrocardiogram), clinical laboratory tests

          2. Age =21 and Age =50 years

          3. BMI =18.5 and BMI =29.9 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP (Good Clinical Practice) and the local legislation

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and considered by the investigator as clinical relevant

          2. Abnormal values for PT (Prothrombin Time) (, aPTT (Partial Thromboplastin Time) and
             trombocytes considered by the investigator as clinically relevant

          3. Any evidence of a clinically relevant concomitant disease

          4. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          5. Surgery of the gastrointestinal tract (except appendectomy)

          6. Diseases of the central nervous system (included but not limited to any kind of
             seizures, stroke or psychiatric disorders)

          7. History of relevant orthostatic hypotension, fainting spells or blackouts.

          8. Chronic or relevant acute infections

          9. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

         10. Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration

         11. Use of drugs which might reasonably influence the results of the trial or that prolong
             the QT/QTc interval based on the knowledge at the time of protocol preparation within
             10 days prior to administration or during the trial

         12. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         13. Smoker, who consume more than 5 cigarettes per day

         14. Inability to refrain from smoking on trial days

         15. Alcohol abuse (more than 20 g/day): 2 units/day (14 units/week)

         16. Drug abuse

         17. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         18. Excessive physical activities (within one week prior to administration or during the
             trial)

         19. Any laboratory value outside the reference range that is of clinical relevance

         20. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTcF interval &gt;450 ms)

         21. Inability to understand and to comply with protocol requirements and restrictions and
             dietary regimen of trial site

         22. of additional risk factors for TdP (Torsades de points) (e.g., heart failure,
             hypokalemia, family history of Long QT Syndrome)

         23. Male subjects who do not agree to minimize the risk of female partners becoming
             pregnant from the first dosing day until three month after the study completion.
             Acceptable methods of contraception comprises barrier contraception and a medically
             accepted contraceptive method for the female (intra-uterine device with spermicide,
             hormonal contraceptive since at least two months)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1289.3.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

